US Pharmacist January 2016
63459091236 - Henry Schein Medical
NDC 63459-910 Granix Tbo-filgrastim
New Granix Syringes Approved for Self-Administration - MPR
Granix® Hematopoietic Agent TBO-Filgrastim, Preservative Free 480 mcg / 0.8 mL Subcutaneous Injection Prefilled Syringe 5 Syringes
BUY tbo-filgrastim (GRANIX) 300 ug/.5mL Cephalon, Inc.
GRANIX (tbo-filgrastim) - PDF Free Download
NDC 63459-910 Granix Tbo-filgrastim
ACTAVIS: Teva Announces Updated Indication and Vial Presentation for GRANIX® (tbo-filgrastim) Injection in United States | American Pharmacy News
Teva's Granix Gets FDA Approval for Expanded Indication
Biosimilar… but different: FDA tweaking nonproprietary name guidance - BioProcess InternationalBioProcess International
Market Share by Filgrastim Brand (As a Percentage of Sales Before Rebates) | Download Scientific Diagram
Resources & Support from Teva CORE | GRANIX
Teva bolsters its biosimilar business through $160m Celltrion deal
Granix - FDA prescribing information, side effects and uses
Teva Is a Hold
Teva - Contract Pharma
Updated Indication For Teva's Granix Injection Approved In U.S. - Drug Discovery and Development
Adverse drug reactions per system organ class reported from... | Download Scientific Diagram
GRANIX Dosage & Rx Info | Uses, Side Effects
These highlights do not include all the information needed to use GRANIX safely and effectively. See full prescribing information for GRANIX.GRANIX® (tbo-filgrastim) injection, for subcutaneous use Initial U.S. Approval: 2012
FDA approves new indication, vial presentation for Teva's Granix | Drug Store News
Granix Indication Expanded to Include Pediatric Patients - MPR
Teva Pharmaceuticals - pdf download
These highlights do not include all the information needed to use GRANIX safely and effectively. See full prescribing information for GRANIX.GRANIX® (tbo-filgrastim) injection, for subcutaneous use Initial U.S. Approval: 2012
